Question 1

What are the main differences between osimertinib and the combination of docetaxel and bevacizumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer clinical trial (NCT02959749). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from each treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer clinical trial (NCT02959749). Contact the study team or your healthcare provider for specific answers.

Question 3

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer clinical trial (NCT02959749). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer clinical trial (NCT02959749). Contact the study team or your healthcare provider for specific answers.

Question 5

What are the logistics of participating, such as visit frequency and treatment duration?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer clinical trial (NCT02959749). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any potential risks I should be aware of with these treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer clinical trial (NCT02959749). Contact the study team or your healthcare provider for specific answers.

What this study is about